Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Hikma Pharmaceuticals PLC
  6. Summary
    HIK   GB00B0LCW083

HIKMA PHARMACEUTICALS PLC

(HIK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/14/2021 10/15/2021 10/18/2021 10/19/2021 10/20/2021 Date
2375(c) 2343(c) 2348(c) 2413(c) 2420 Last
308 342 327 724 175 357 324 584 185 838 Volume
+1.15% -1.35% +0.21% +2.77% +0.29% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 2 507 M - -
Net income 2021 431 M - -
Net Debt 2021 292 M - -
P/E ratio 2021 18,3x
Yield 2021 1,67%
Sales 2022 2 735 M - -
Net income 2022 486 M - -
Net Debt 2022 66,5 M - -
P/E ratio 2022 16,3x
Yield 2022 1,84%
Capitalization 7 703 M 7 719 M -
EV / Sales 2021 3,19x
EV / Sales 2022 2,84x
Nbr of Employees 8 600
Free-Float 67,7%
More Financials
Company
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The Company sells... 
More about the company
Ratings of Hikma Pharmaceuticals PLC
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about HIKMA PHARMACEUTICALS PLC
08:34aHIKMA PHARMACEUTICALS : Barclays Lifts Hikma Pharmaceuticals PT, Keeps Overweight Rating
MT
10/19WALL STREET STOCK EXCHANGE : Earnings season continues to deliver
10/19ANALYST RECOMMENDATIONS : Apple, Goldman Sachs, Netflix, S&P Global, UnitedHealth...
09/30HIKMA PHARMACEUTICALS : Glenmark Secures Nasal Spray Marketing Approval In 14 European Cou..
MT
09/30GLENMARK PHARMACEUTICALS : Gets Nod to Market Nasal Spray in Europe
MT
09/27HIKMA PHARMACEUTICALS : Citigroup Maintains Hikma Pharmaceuticals At Buy, Lifts PT
MT
09/27Energy stocks, banks lift FTSE 100; Rolls-Royce top performer
RE
09/27HIKMA PHARMACEUTICALS : Drugmaker Hikma to buy U.S.-based Custopharm to boost needle-based..
RE
09/27FTSE 100 Seen Opening Higher
DJ
09/27HIKMA PHARMACEUTICALS : To Buy US-Based Generics Group Custopharm For $425 Milion
MT
09/27Hikma Pharmaceuticals PLC agreed to acquire Custopharm Inc. from Water Street Healthcar..
CI
09/23HIKMA PHARMACEUTICALS : Generics Meet the Management Presentation
PU
09/02HIKMA PHARMACEUTICALS : Barclays Boosts Hikma Pharmaceutical PT, Keeps Overweight Rating
MT
08/27HIKMA PHARMACEUTICALS : Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive C..
BU
08/27Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and ..
CI
More news
News in other languages on HIKMA PHARMACEUTICALS PLC
10/19OPINIONES DE LOS ANALISTAS DEL DÍA : Endesa, IAG, Umicore, Prosus, Aston Martin, EasyJet, ..
10/19AVIS D'ANALYSTES DU JOUR : Air France-KLM, Ipsen, JCDexaux, Umicore, Prosus, Aston Martin,..
09/30Glenmark obtient l'autorisation de commercialisation du spray nasal dans 14 pays europé..
09/30Glenmark Pharmaceuticals obtient le feu vert pour commercialiser un spray nasal en Euro..
09/27Hikma va racheter le groupe américain de génériques Custopharm pour 425 millions de dol..
More news
Analyst Recommendations on HIKMA PHARMACEUTICALS PLC
More recommendations
Chart HIKMA PHARMACEUTICALS PLC
Duration : Period :
Hikma Pharmaceuticals PLC Technical Analysis Chart | HIK | GB00B0LCW083 | MarketScreener
Technical analysis trends HIKMA PHARMACEUTICALS PLC
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 33,28 $
Average target price 38,42 $
Spread / Average Target 15,4%
EPS Revisions
Managers and Directors
Sigurdur Oli Olafsson Chief Executive Officer & Director
Khalid Walid Hosni Nabilsi Chief Financial Officer
Said Samih Taleb Darwazah Executive Chairman
Shahin Fesharaki Chief Scientific Officer
Henriette Nielsen Executive Vice President-Business Operations
Sector and Competitors
1st jan.Capi. (M$)
HIKMA PHARMACEUTICALS PLC-4.17%7 708
JOHNSON & JOHNSON4.12%431 385
ROCHE HOLDING AG15.84%337 562
NOVO NORDISK A/S57.04%239 813
PFIZER, INC.12.25%235 986
ELI LILLY AND COMPANY43.51%219 674